Published in J Neurochem on February 01, 1981
Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab (1995) 1.54
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry (2004) 1.44
Clinical drug monitoring by microdialysis: application to levodopa therapy in Parkinson's disease. Br J Clin Pharmacol (1996) 1.39
Visual field constriction: accumulation of vigabatrin but not tiagabine in the retina. Neurology (2001) 1.36
The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy. Epilepsy Res (1990) 1.30
Familial alpha-lipoprotein deficiency (Tangier disease) with neurological abnormalities. Lancet (1967) 1.22
Hypodipsia and hypernatraemia associated with hypothalamic and suprasellar lesions. Brain (1972) 1.09
The distribution of plasma phenytoin levels in epileptic patients. J Neurol Neurosurg Psychiatry (1970) 1.07
A disorder of skeletal muscle associated with tubular aggregates. Brain (1970) 1.07
Plasma control in psychiatric and neurological patients with pain. Brain (1974) 1.05
Effect of sodium valproate on plasma protein binding of diphenylhydantoin. J Neurol Neurosurg Psychiatry (1977) 1.04
Valproate may lower serum-phenytoin. Lancet (1977) 1.02
Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res (1999) 1.00
A comparative pharmacokinetic study of intravenous and intramuscular midazolam in patients with epilepsy. Epilepsy Res (1992) 0.99
Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: a study with positron emission tomography. J Am Coll Cardiol (1993) 0.99
Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia (2000) 0.99
A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res (1990) 0.98
Measurement of prostaglandin F2alpha in human cerebrospinal fluid by single ion monitoring. Biomed Mass Spectrom (1976) 0.98
A microdialysis study of the novel antiepileptic drug levetiracetam: extracellular pharmacokinetics and effect on taurine in rat brain. Br J Pharmacol (2001) 0.97
Side-effects induced by carbamazepine-10,11-epoxide. Lancet (1985) 0.97
The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res (1993) 0.96
Investigation into the role of N-acetylaspartate in cerebral osmoregulation. J Neurochem (1995) 0.96
Acute diphenylhydantoin and primidone poisoning treated by peritoneal dialysis. J Neurol Neurosurg Psychiatry (1968) 0.94
The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs (2001) 0.93
Lamotrigine-induced carbamazepine toxicity: an interaction with carbamazepine-10,11-epoxide. Epilepsy Res (1992) 0.93
Determination of clobazam and desmethylclobazam in serum using high-performance liquid chromatography. Analyst (1984) 0.93
An X-linked disease of the nervous system with disordered copper metabolism and features differing from Menkes disease. Neurology (1981) 0.92
Regional studies of changes in brain fatty acids following experimental ischaemia and reperfusion in the gerbil. J Neurochem (1984) 0.90
Microdialysis study of the neuropharmacokinetics of phenytoin in rat hippocampus and frontal cortex. Epilepsia (1996) 0.90
Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. Clin Neuropharmacol (1994) 0.89
Routine monitoring of carbamazepine and carbamazepine-10,11-epoxide in plasma by high-performance liquid chromatography using 10-methoxycarbamazepine as internal standard. J Chromatogr (1982) 0.88
A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Ther Drug Monit (1996) 0.88
Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br J Pharmacol (2000) 0.87
Comparison of single- and repeated-dose pharmacokinetics of diazepam. Epilepsia (1998) 0.86
Copper-64 metabolism in two patients with non-Wilsonian movement disorders and copper deficiency. J Neurol Sci (1993) 0.86
Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population. Ther Drug Monit (2001) 0.85
Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur J Pharmacol (1997) 0.85
Factors influencing simultaneous concentrations of total and free carbamazepine and carbamazepine-10, 11-epoxide in serum of children with epilepsy. Ther Drug Monit (1986) 0.84
An assessment of serum 57Co cyanocobalamin as an index of vitamin B12 absorption. J Clin Pathol (1970) 0.83
Correlation between plasma carbamazepine-10,11-epoxide concentration and drug side-effects in children with epilepsy. Dev Med Child Neurol (1984) 0.83
Hair analysis as a potential index of therapeutic compliance in the treatment of epilepsy. Forensic Sci Int (1997) 0.83
Comparison of topiramate concentrations in plasma and serum by fluorescence polarization immunoassay. Ther Drug Monit (2000) 0.83
Oxygen electrode studies of rat brain respiration in hepatic coma. Exp Biol Med (1971) 0.83
Glucose tolerance and plasma insulin levels in subarachnoid haemorrhage. Brain (1971) 0.83
Transport of intravenously administered 131-I RIHSA into primary hydroceles and the tunical sac of patients undergoing herniorrhaphy. Br J Surg (1969) 0.82
Intravenous apomorphine therapy in Parkinson's disease: clinical and pharmacokinetic observations. Brain (2001) 0.82
Simple and rapid micro-analytical high-performance liquid chromatographic technique for the assay of oxcarbazepine and its primary active metabolite 10-hydroxycarbazepine. J Chromatogr (1990) 0.82
Determination of diazepam and its major metabolites using high-performance liquid chromatography. Analyst (1981) 0.81
Drugs used in the management of trigeminal neuralgia. Oral Surg Oral Med Oral Pathol (1992) 0.81
Concurrent monitoring of central carbamazepine and transmitter amine metabolism and motor activity in individual unrestrained rats using repetitive withdrawal of cerebrospinal fluid. Neuropharmacology (1988) 0.81
Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J Neurol Neurosurg Psychiatry (1989) 0.81
The effect upon tissue respiration in vitro of metabolites which may accumulate in hepatic coma. Clin Sci (1968) 0.81
Immediate anticonvulsive drug monitoring in management of epilepsy. Lancet (1987) 0.81
Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure (1994) 0.81
Halothane as a neuroprotectant during constant stimulation of the perforant path. Epilepsia (1999) 0.80
Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther (1995) 0.80
A case of Noonan's syndrome and hypoparathyroidism presenting with epilepsy. J Neurol Neurosurg Psychiatry (1974) 0.80
An assessment of serum and red blood cell folate concentrations in patients with epilepsy on lamotrigine therapy. Epilepsy Res (1992) 0.80
An unusual neurological disorder of copper metabolism clinically resembling Wilson's disease but biochemically a distinct entity. J Neurol Sci (1978) 0.79
Simple and rapid micro-analytical procedures for the estimation of milacemide and its metabolite glycinamide in rat plasma and cerebrospinal fluid by high-performance liquid chromatography. J Chromatogr (1991) 0.79
A high-performance liquid-chromatographic microanalytical procedure for the rapid estimation of piracetam in plasma or cerebrospinal fluid. J Pharm Pharmacol (1996) 0.79
A comparison of the efficacy of carbamazepine and the novel anti-epileptic drug levetiracetam in the tetanus toxin model of focal complex partial epilepsy. Br J Pharmacol (2002) 0.79
Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide. Br J Pharmacol (1993) 0.78
Blood and cerebrospinal fluid pharmacokinetics of primidone and its primary pharmacologically active metabolites, phenobarbital and phenylethylmalonamide in the rat. Eur J Drug Metab Pharmacokinet (2000) 0.78
Vitamin B12 absorption in some neurological and neuroendocrine disorders. J Clin Pathol (1970) 0.78
Side-effects induced by carbamazepine-10,11-epoxide. Lancet (1986) 0.78
Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy. J Clin Pathol (1991) 0.78
Caffeine has no effect on measures of cortical excitability. Clin Neurophysiol (2005) 0.78
A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. Mov Disord (1995) 0.78
The synthesis of myelin and brain subcellular membrane proteins in the offspring of rats fed ethanol during pregnancy. Brain Res (1982) 0.78
Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: phenytoin. Epilepsy Res (1994) 0.78
Effect of gestational age on levels of serum alkaline phosphatase isoenzymes in healthy pregnant women. Int J Gynaecol Obstet (1995) 0.78
Carbamazepine and carbamazepine-10,11-epoxide pharmacokinetics in an overdose patient. Hum Toxicol (1987) 0.78
Effects of discontinuation of phenytoin, carbamazepine, and valproate on concomitant antiepileptic medication. Epilepsia (1991) 0.77
Effect of felbamate and its combinations with conventional antiepileptics in amygdala-kindled rats. Pharmacol Biochem Behav (2004) 0.77
Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex. Br J Pharmacol (1992) 0.77
Brain myelination in the offspring of ethanol-treated rats: in utero versus lactational exposure by crossfostering offspring of control, pairfed and ethanol treated dams. Brain Res (1984) 0.77
Cortical excitability predicts seizures in acutely drug-reduced temporal lobe epilepsy patients. Neurology (2006) 0.77
Clinical implications of sustained dopaminergic stimulation. Clin Neuropharmacol (1994) 0.77
Milacemide effects on the temporal inter-relationship of amino acids and monoamine metabolites in rat cerebrospinal fluid. Eur J Pharmacol (1993) 0.76
Antiepileptic drugs, hepatic enzyme induction and raised serum alkaline phosphatase isoenzymes. Int J Clin Pharmacol Res (1990) 0.76
Brain maturation following administration of phenobarbital, phenytoin, and sodium valproate to developing rats or to their dams: effects on synthesis of brain myelin and other subcellular membrane proteins. J Neurochem (1982) 0.76
An evaluation of the epileptogenic properties of a rifampicin/clindamycin-impregnated shunt catheter. Br J Neurosurg (1994) 0.75
Cerebral depression due to propylene glycol in a patient with chronic epilepsy--the value of the plasma osmolal gap in diagnosis. Postgrad Med J (1988) 0.75
Pattern of myelin breakdown during sciatic nerve Wallerian degeneration: reversal of the order of assembly. J Cell Biol (1980) 0.75
Allopurinol as an add-on drug in the management of intractable epilepsy. Epilepsy Res (1989) 0.75
An assessment of serum 57Co cyanocobalamin as an index of vitamin B12 absorption. J Clin Pathol (1968) 0.75
The interaction of denzimol (a new anticonvulsant) with carbamazepine and phenytoin. J Neurol Neurosurg Psychiatry (1985) 0.75
A high-performance liquid chromatography micromethod for the simultaneous determination of vigabatrin and gabapentin in serum. Ther Drug Monit (1998) 0.75
Disabling tremor after lamotrigine with sodium valproate. Lancet (1993) 0.75
Induced metabolic alkalosis in hepatic encephalopathy. Lancet (1969) 0.75
Some practical applications of biochemistry to physiotherapy. Physiotherapy (1972) 0.75
The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid. Seizure (2006) 0.75